J. Safra Asset Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

J. Safra Asset Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.3M	Buy	310,801 +5,329	+2%	+$568K	1.74%	15
2025 Q4	$31.5M	Buy	305,472 +19,685	+7%	+$1.91M	1.65%	16
2025 Q3	$25.8M	Buy	285,787 +12,011	+4%	+$1.05M	1.57%	16
2025 Q2	$24.1M	Buy	273,776 +4,950	+2%	+$429K	1.68%	16
2025 Q1	$24.5M	Buy	268,826 +8,559	+3%	+$771K	1.99%	16
2024 Q4	$22.4M	Buy	260,267 +181,511	+230%	+$16.4M	1.82%	17
2024 Q3	$7.47M	Buy	78,756 +5,147	+7%	+$489K	0.71%	19
2024 Q2	$6.73M	Buy	73,609 +4,084	+6%	+$365K	0.68%	19
2024 Q1	$6.31M	Buy	+69,525	New	+$6.09M	0.71%	18

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

J. Safra Asset Management's PPH Position: Q1 2026 in Review

J. Safra Asset Management increased its VanEck Pharmaceutical ETF (PPH) stake by 1.7% in Q1 2026, buying an estimated $568K and bringing the position to 310,801 shares worth $32.3M. The position accounts for 1.74% of the portfolio, ranked #15.

J. Safra Asset Management first reported a position in PPH in Q1 2024 and has held it in 9 quarters since. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

J. Safra Asset Management held 310,801 shares of VanEck Pharmaceutical ETF worth $32.3M as of Q1 2026.
J. Safra Asset Management bought 5,329 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $568K.
VanEck Pharmaceutical ETF made up 1.74% of J. Safra Asset Management's portfolio in Q1 2026, its #15 holding.
J. Safra Asset Management first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and has held it in 9 quarters since.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.